StreetInsider.com News Articles

Form 8-K Silo Pharma, Inc. For: Oct 13

Wed, 14 Oct 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20261014/27187498.html

Form 8-K Silo Pharma, Inc. For: Oct 01

Fri, 02 Oct 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20261002/27142969.html

Silo Pharma's QwikAgents adds Nvidia model support and second runtime

Wed, 30 Sep 2026 08:50:57 -0400

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, announced that its wholly owned AI subsidiary QwikAgents has added support for customer-supplied Nvidia API keys and a second agent runtime called Hermes to its managed AI agent platform.

Customers can now connect their own Nvidia API keys to access Nvidia's Nemotron models through QwikAgents. The platform includes automated model routing designed to maintain agent availability. Nvidia becomes the fifth bring-your-own-key provider supported on the platform, alongside Anthropic, OpenAI, Google, and DeepSeek. QwikAgents joined the Nvidia Developer Program in July 2026.

At the software layer, QwikAgents added Hermes as an alternative agent runtime to

Silo Pharma’s QwikAgents Expands AI Agent Platform with NVIDIA Model Support and New Runtime Flexibility

Wed, 30 Sep 2026 08:50:00 -0400

Addition of NVIDIA Nemotron models and Hermes runtime expands customer choice across both AI models and agent software

SARASOTA, FLA., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems with a wholly owned managed AI agent subsidiary QwikAgents, today announced that QwikAgents has expanded its AI agent platform with new customer choice across both AI models and agent software, including support for customer-supplied NVIDIA API keys and the addition of Hermes agent runtime. The new capabilities are available

Silo Pharma’s QwikAgents Expands AI Agent Platform with NVIDIA Model Support and New Runtime Flexibility

Wed, 30 Sep 2026 08:50:00 -0400

Addition of NVIDIA Nemotron models and Hermes runtime expands customer choice across both AI models and agent software

USPTO allows Silo Pharma patent for SPC-15 PTSD treatment

Fri, 18 Sep 2026 08:50:10 -0400

Silo Pharma (Nasdaq: SILO) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering SPC-15, its intranasal therapeutic candidate targeting post-traumatic stress disorder (PTSD).

The patent, titled "Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior," covers both composition and method claims related to preventing or mitigating stress-induced behavioral responses. A Notice of Allowance indicates the USPTO has completed its examination and determined the application meets patentability requirements; the patent is expected to be granted shortly.

A corresponding patent for the same invention was previously issued by the Japan

Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio

Fri, 18 Sep 2026 08:50:00 -0400

Allowed claims cover compositions and methods for preventing or mitigating stress-induced behavioral responses

SARASOTA, FLA., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems with a wholly owned managed AI agent platform, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, a novel intranasal therapeutic targeting post-traumatic stress disorder (PTSD).

The invention, titled “Compositions and Methods for the Prevention of Stress-Induced

Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio

Fri, 18 Sep 2026 08:50:00 -0400

Allowed claims cover compositions and methods for preventing or mitigating stress-induced behavioral responses

The invention, titled “Compositions and Methods for the Prevention of Stress-Induced

Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum

Wed, 09 Sep 2026 09:15:00 -0400

SARASOTA, FLA., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), ”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems with a wholly owned managed AI agent platform, today announced that company representatives will participate in the upcoming IPAC-RS 2026 Nasal Innovation Forum to be held September 16-17, 2026, in Jersey City, New Jersey.

The International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) has served as a leading global voice for the inhaled and nasal drugs and biologics (INDB) industry for more than 25 years. IPAC-RS

Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum

Wed, 09 Sep 2026 09:15:00 -0400

Silo Pharma acquires software assets from Parkview Consulting for stock

Wed, 19 Aug 2026 17:20:25 -0400

Silo Pharma, Inc. (NASDAQ: SILO) entered into an asset purchase agreement with Parkview Consulting LLC on August 18, 2026, acquiring software, technology, domain names, and related intellectual property.

In exchange for the assets, Silo Pharma issued 165,000 shares of common stock, par value $0.0001 per share, to Parkview Consulting. The shares are subject to a lock-up period lasting up to 12 months from the agreement's effective date, or until a change of control occurs or the company provides written consent to release the restriction.

Corwin Yu, the sole member and manager of Parkview Consulting, currently serves as the lead strategic advisor on

Silo Pharma acquires software assets from Parkview Consulting for stock

Wed, 19 Aug 2026 17:20:25 -0400

Corwin Yu, the sole member and manager of Parkview Consulting, currently serves as the lead strategic advisor on

Form 8-K Silo Pharma, Inc. For: Aug 18

Wed, 19 Aug 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260819/26951151.html

Form 8-K Silo Pharma, Inc. For: Aug 18

Wed, 19 Aug 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260819/26951151.html

Silo Pharma receives Canadian patent allowance for PTSD drug SPC-15

Tue, 18 Aug 2026 16:15:18 -0400

Silo Pharma (NASDAQ: SILO) announced that the Canadian Intellectual Property Office has issued a Notice of Allowance for a patent application covering SPC-15, the company's intranasal 5-HT4 receptor agonist being developed for post-traumatic stress disorder and other stress-induced psychiatric disorders.

The allowed application, titled "Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress," covers methods of preventing or delaying stress-induced fear and depressive-like behavior, as well as methods for inducing or enhancing stress resilience by administering 5-HT4 receptor agonists prior to a stressor.

Silo holds an exclusive license for the Canadian patent application under a broader agreement with Columbia University to develop,

Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment

Tue, 18 Aug 2026 16:15:00 -0400

Follows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic program

SARASOTA, FLA., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems with a wholly owned managed AI agent platform subsidiary, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, an intranasal 5-HT4 receptor agonist targeting post-traumatic stress disorder (PTSD) and other stress-induced

Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment

Tue, 18 Aug 2026 16:15:00 -0400

Follows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic program

Form 8-K Silo Pharma, Inc. For: Aug 14

Mon, 17 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260817/26937965.html

Form 8-K Silo Pharma, Inc. For: Aug 14

Mon, 17 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260817/26937965.html

Form 10-Q Silo Pharma, Inc. For: Jun 30

Thu, 13 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260813/26920918.html

Form 10-Q Silo Pharma, Inc. For: Jun 30

Thu, 13 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260813/26920918.html

Form SCHEDULE 13G/A Silo Pharma, Inc. Filed by: INTRACOASTAL CAPITAL, LLC

Thu, 13 Aug 2026 10:22:00 -0400

si-local-file:///var/storage/secattach/20260813/26918146.html

Form SCHEDULE 13G/A Silo Pharma, Inc. Filed by: INTRACOASTAL CAPITAL, LLC

Thu, 13 Aug 2026 10:22:00 -0400

si-local-file:///var/storage/secattach/20260813/26918146.html

Silo Pharma receives European patent for preventative PTSD treatment

Mon, 10 Aug 2026 08:15:29 -0400

Silo Pharma (NASDAQ: SILO) announced that the European Patent Office has granted European Patent No. EP3952852, covering the preventative approach of its lead candidate SPC-15, an intranasal treatment targeting post-traumatic stress disorder and stress-induced affective disorders.

The patent, titled "Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress," covers methods of preventing stress-induced fear, depressive-like behavior, and associated affective disorders by administering serotonin 4 (5-HT4) receptor agonists before exposure to a stressor.

Silo Pharma holds an exclusive license for the European patent from Columbia University, which also covers development, manufacturing, and commercialization of SPC-15 globally.

Eric Weisblum, Chief Executive Officer of Silo Pharma,

Silo Pharma Granted European Patent Covering Novel PTSD Therapy

Mon, 10 Aug 2026 08:15:00 -0400

Patent strengthens global IP protection for novel treatment approach designed to prevent stress-induced psychiatric disorders before symptoms develop

SARASOTA, FLA., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a managed AI agent platform and developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the European Patent Office (EPO) has granted a patent covering the preventative approach of its lead candidate SPC-15, a novel intranasal, nose-to-brain treatment targeting post-traumatic stress disorder (PTSD) and stress-induced affective disorders. The Company has an exclusive license for the European